<DOC>
	<DOCNO>NCT00442624</DOCNO>
	<brief_summary>We aim assess influence chronic insomnia neuroendocrine regulation glucose lipid metabolism clearly define metabolic derangement associate chronic insomnia prove chronic insomnia associate increased level stress hormone , cytokine impair insulin sensitivity .</brief_summary>
	<brief_title>Effects Chronic Insomnia Neuroendocrine Regulation Glucose Lipid Metabolism</brief_title>
	<detailed_description>Sleep fragmentation previously show result activation stress axis indicate enhanced cortisol catecholamine release proinflammatory state mirror increased concentration proinflammatory cytokine IL-6 TNFa . Therefore sleep deprivation associate similar pattern endocrine proinflammatory alteration may promote insulin resistant state . Thus , paramount interest clearly define metabolic alteration patient primary insomnia . Patients suspect primary insomnia recruit sleep clinic University Hospital Basel newspaper ad . Primary insomnia diagnose polysomnographic study exclusion secondary cause depression , sleep apnea restless legs syndrome . Eligible patient admit CRC metabolic study , include baseline blood sample measurement hormone , cytokine adipokines , euglycemic-hyperinsulinemic clamp study assessment glucose turnover insulin sensitivity vivo NMR study determine intrahepatic intramyocellular lipid content . The data obtain insomnic patient compare control group match age , sex , BMI , menopausal status physical activity select general population .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<criteria>â€¢ Patients primary chronic insomnia base clinical history polysomnographic study . Diabetes mellitus Known sleep disorder , depression , obstructive sleep apnea restless legs syndrome Alcohol consumption &gt; 40 g / male , &gt; 20 g / female , respectively , Patients treat medication potentially interfere glucose metabolism , systemic steroid , immunosuppressive drug ( cyclosporine , tacrolimus , sirolimus ) , highly active antiretroviral therapy , hydrochlorothiazide &gt; 25 mg/d Patients treat lipid lower drug statin , fibrates , nicotinic acid derivative , resin ezetimibe lipid lower therapy safely withheld duration study . Patients LDLcholesterol concentration &gt; 4.9 mmol/l fast triglyceride concentration &gt; 12 mmol/l . Any significant unstable hepatic , cardiac , pulmonary , renal , neurological , musculoskeletal , hematological endocrine disease . Pregnant Breast Feeding woman Woman childbearing potential use reliable method birth control oral contraceptive IUD . History claustrophobia Ferromagnetic implant include pacemaker . Subjects refuse unable give write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>insomnia</keyword>
	<keyword>glucose metabolism</keyword>
	<keyword>insulin resistance</keyword>
</DOC>